^
Association details:
| Biomarker: | CXCL11 elevation |
|---|---|
| Cancer: | Follicular Lymphoma |
| Drug: | Copiktra (duvelisib) (PI3Kδ inhibitor, PI3Kγ inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMOTM Clinical Trial in iNHL
Published date:
11/01/2018
Excerpt:
In the Phase 2 DYNAMO trial of duvelisib monotherapy for relapsed/refractory iNHL....for FL pts between high and low risk subgroups stratified by prognostic indexes...shorter mPFS was associated with higher levels of CXCL11 (9.0 moL, n=39 vs 5.6 moH, n=32) and IL2RA (9.0 moL, n=36 vs 5.6 moH, n=35)...Elevated levels of CXCL11 and IL2RA correlated with shorter mPFS.
DOI:
10.1182/blood-2018-99-117903
Trial ID:
